A Study of EBC-129 in Advanced Solid Tumours

• ClinicalTrials.gov Identifier: NCT05701527
• Recruitment Status: Recruiting
• First Posted: January 27, 2023
• Last Update Posted: April 15, 2024
• Sponsor: EDDC (Experimental Drug Development Centre), A*STAR Research Entities
• Collaborator: Parexel
• Information provided by (Responsible Party): EDDC (Experimental Drug Development Centre), A*STAR Research Entities

Study Description

Brief Summary:

This study will assess the safety and tolerability of EBC-129 as a single agent and in combination with pembrolizumab in patients with advanced solid tumours

Condition or disease	Intervention/treatment	Phase
Advanced Solid Tumours	Drug: EBC-129; Drug: Pembrolizumab	Phase 1

Detailed Description:

This study is a prospective, open label study which is divided into 3 parts.

Part A will be dose escalation segment to identify the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of EBC-129 monotherapy.

Part B will be dose escalation segment to identify the MTD and RP2D of EBC-129 in combination with pembrolizumab.

Part C (dose expansion cohort) will be performed in an expanded cohort of patients with advanced solid malignancies at the RP2D of EBC-129 as a monotherapy identified in the dose escalation segment, Part A.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 84 participants
• Allocation: Non-Randomized
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase 1A/B Study To Evaluate The Safety And Tolerability Of EBC-129 As A Single Agent And In Combination With Pembrolizumab In Advanced Solid Tumours
• Actual Study Start Date: April 28, 2023
• Estimated Primary Completion Date: June 11, 2026
• Estimated Study Completion Date: June 11, 2026

Arms and Interventions

Arm	Intervention/treatment
Experimental: Part A-Cohort 1; Patients will be administered Dose 1 of EBC-129 as a monotherapy.	Drug: EBC-129; EBC-129 will be administered on Day 1 of each 21-Day cycle via a 30-120-minute intravenous (IV) fusion.
Experimental: Part A-Cohort 2; Patients will be administered Dose 2 of EBC-129 as a monotherapy.	Drug: EBC-129; EBC-129 will be administered on Day 1 of each 21-Day cycle via a 30-120-minute intravenous (IV) fusion.
Experimental: Part A-Cohort 3; Patients will be administered Dose 3 of EBC-129 as a monotherapy.	Drug: EBC-129; EBC-129 will be administered on Day 1 of each 21-Day cycle via a 30-120-minute intravenous (IV) fusion.
Experimental: Part A-Cohort 4; Patients will be administered Dose 4 of EBC-129 as a monotherapy.	Drug: EBC-129; EBC-129 will be administered on Day 1 of each 21-Day cycle via a 30-120-minute intravenous (IV) fusion.
Experimental: Part A-Cohort 5; Patients will be administered Dose 5 of EBC-129 as a monotherapy.	Drug: EBC-129; EBC-129 will be administered on Day 1 of each 21-Day cycle via a 30-120-minute intravenous (IV) fusion.
Experimental: Part B; Patients will be administered three different dose levels of EBC-129 in combination with a fixed dose of pembrolizumab.	Drug: EBC-129; EBC-129 will be administered on Day 1 of each 21-Day cycle via a 30-120-minute intravenous (IV) fusion.; Drug: Pembrolizumab; Pembrolizumab will be administered at the dose of 200 mg IV every 21 days.
Experimental: Part C; Patients will be administered the highest dose of EBC-129 as a monotherapy at the RP2D determined in Part A of the study.	Drug: EBC-129; EBC-129 will be administered on Day 1 of each 21-Day cycle via a 30-120-minute intravenous (IV) fusion.

Outcome Measures

Primary Outcome Measures :

1. Part A, Part B and Part C- Number of patients with serious adverse events (SAEs) and treatment emergent adverse events (TEAEs) [ Time Frame: From pre-screening (≥28 days from planned date of treatment i.e. Day 1) until end of study (EOS i.e., 30 days from last dose). Approximately 2 years ]
2. Part A and Part B- Determination of Maximum tolerated dose (MTD) [ Time Frame: Approximately 2 years ]
3. Part A and Part B- Determination of the Recommended Phase 2 dose (RP2D) [ Time Frame: Approximately 2 years ]
4. Part C- Objective response rate (ORR) [ Time Frame: Day 1 through 12 cycles (each cycle is 21 days) ]
   The number (%) of patients with a best overall response of complete response (CR) or partial response (PR) per RECIST v1.1 as assessed by investigator.

Secondary Outcome Measures :

1. Part A and Part B- ORR [ Time Frame: Day 1 through 12 cycles (each cycle is 21 days) ]
   The number (%) of patients with a best overall response of complete response (CR) or partial response (PR) per RECIST v1.1 as assessed by investigator.
2. Part A, Part B and Part C- Disease control rate (DCR) [ Time Frame: Approximately 3.3 years ]
   The percentage of patients who have a best overall response (BOR) of CR or PR in the first 12 weeks or who have demonstrated standard deviation (SD) for a minimum interval of 12 weeks following the start of treatment, will be determined based on RECIST.
3. Part A, Part B and Part C- Duration of Response (DoR) [ Time Frame: Approximately 3.3 years ]
   The time from the date of first documented response until the first date of documented progression or death in the absence of disease progression.
4. Part A, Part B and Part C- Time to Progression (TTP) [ Time Frame: Approximately 3.3 years ]
   The time from the date of the first dose until objective tumour progression.
5. Part A, Part B and Part C- Progression Free Survival (PFS) [ Time Frame: Approximately 3.3 years ]
   The time from the date of first dose until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anti-cancer therapy prior to progression.
6. Part A, Part B and Part C- Overall Survival (OS) [ Time Frame: Approximately 3.3 years ]
   The time from the date of the first dose until death due to any cause.
7. Part A, Part B and Part C- Maximum Plasma Concentration (Cmax) of EBC-129 [ Time Frame: Cycle 1, 2, 3, and Cycle 4 (each cycle is 21 days) ]
8. Part A, Part B and Part C- Trough Concentration (Ctrough) of EBC-129 [ Time Frame: Cycle 1, 2, 3, and Cycle 4 (each cycle is 21 days) ]
9. Part A, Part B and Part C- Area under the plasma drug concentration-time curve from time zero to Day 21 post-dose (AUC0-21d) of EBC-129 [ Time Frame: Cycle 1 and Cycle 2 (each cycle is 21 days) ]
10. Part A, Part B and Part C- Maximum plasma concentration at steady state (Cmax_ss) [ Time Frame: Day 1 through 12 cycles (each cycle is 21 days) ]
11. Part A, Part B and Part C- Trough concentration (Ctrough,ss) [ Time Frame: Day 1 through 12 cycles (each cycle is 21 days) ]
12. Part A, Part B and Part C- Area under the curve at steady state (AUC0-21d_ss) [ Time Frame: Day 1 through 12 cycles (each cycle is 21 days) ]
13. Part A, Part B and Part C- Accumulation ratios [ Time Frame: Day 1 through 12 cycles (each cycle is 21 days) ]
14. Part A, Part B and Part C- Time to maximum plasma concentration (Tmax) of EBC-129 [ Time Frame: Day 1 through 12 cycles (each cycle is 21 days) ]
15. Part A, Part B and Part C- Half-life (t1/2) of EBC-129 [ Time Frame: Day 1 through 12 cycles (each cycle is 21 days) ]
16. Part B- Cmax of Pemrolizumab [ Time Frame: Day 1 through 12 cycles (each cycle is 21 days) ]
17. Part B- Ctrough of Pemrolizumab [ Time Frame: Day 1 through 12 cycles (each cycle is 21 days) ]
18. Part B- AUC0-21d of Pemrolizumab [ Time Frame: Cycle 1 and 2 (each cycle is 21 days) ]
19. Part B- Tmax of Pemrolizumab [ Time Frame: Day 1 through 12 cycles (each cycle is 21 days) ]
20. Part B- t1/2 of Pemrolizumab [ Time Frame: Day 1 through 12 cycles (each cycle is 21 days) ]
21. Part A, Part B and Part C- Number of patients with detectable Anti-drug antibodies (ADAs) [ Time Frame: Day 1 through 12 cycles (each cycle is 21 days) ]
22. Part A, Part B and Part C- Number of patients with neutralising antibodies [ Time Frame: Day 1 through 12 cycles (each cycle is 21 days) ]
23. Part A- Comparison of tumour responses [ Time Frame: Approximately 1.8 years ]
    The tumour responses (RECIST 1.1) will be compared between preselected patients and not pre-selected/not expressing the antigen when centrally assessed by immunohistochemistry (IHC).

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Male or female patients ≥18 years (US) or ≥21 years (Singapore) old
2. Body weight within ≥40 kg - ≤100 kg during Parts A and B, and ≤120 kg during all other parts of the study
3. Demonstrated progression of a locally advanced unresectable or metastatic solid tumour with no alternative standard-of-care therapeutic option with a proven clinical benefit, or are intolerant to these therapies
4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2
5. Hepatic function and adequate renal function, as per protocol standard
6. Adequate bone marrow function as per protocol standard

Exclusion Criteria:

1. Unable or not willing to provide tumour tissue sample (from archival tissue or de-novo biopsy) unless if there is a significant risk for the patient to undergo biopsy
2. Has received investigational or anti-cancer therapy within 4 weeks (28 days) prior to starting study drug
3. Is receiving any concomitant anti-cancer therapy
4. Known severe hypersensitivity to E coli-derived products or filgrastim or peg-filgrastim and have significant allergies to such biological products
5. Has clinically active brain metastases
6. Has received prior radiation therapy
7. Has received prophylactic administration of haematopoietic colony stimulating factors within 4 weeks (28 days) prior to starting study drug
8. Patients concurrently using any strong P-glycoprotein (P-gp) inducers/inhibitors or strong cytochrome P3A (CYP3A) inhibitors within 14 days prior to the first dose of study drug or patients that use restricted or prohibited medications listed in the concomitant and other treatments section of the protocol
9. Pregnancy or breast feeding

10. For patients receiving pembrolizumab:

    1. Has an active autoimmune disease that has required systemic treatment in the past 2 years
    2. Patients who, according to the currently approved Keytruda (pembrolizumab) US package insert (USPI)/summary of product characteristics, had an immune-related adverse event (irAE) for which permanent discontinuation is mandated (any Grade 4 event and Grade 3 events of pneumonitis, hepatitis, and nephritis). Also, patients without formal contraindication due to previous irAE with any immune checkpoint inhibitor (approved or investigational) are not eligible if the AE has not resolved to grade 1 or better and/or still requires steroids (>10 mg of prednisone equivalent per day) for ongoing management.
    3. Patients with a history of pneumonitis/interstitial lung disease, patients who received live vaccines within 30 days of enrolment, and patients who discontinued prior immune checkpoint inhibitors due to Grade 2 myocarditis are excluded from enrolment into pembrolizumab-containing cohorts
11. Has had a major surgical procedure within 4 weeks (28 days) from starting the study drug
12. Patients with active or chronic corneal disorders, with other active ocular conditions requiring ongoing therapy or with any clinically significant corneal disease that prevents adequate monitoring of drug-induced keratopathy
13. Active infection including HIV, Hepatitis B or Hepatitis C

Contacts and Locations

Contacts

Contact: Venkateshan Srirangam Prativadibhayankara, MD; +65 6407 4213; Venkateshan_Srirangam@eddc.sg

Contact: Veronica Diermayr; +65 6407 0706; Veronica_Diermayr@eddc.sg

Locations

United States, Colorado

University of Colorado Hospital (UCH) - University of Colorado Cancer Center (UCCC) - Neuroendocrine Tumor Center; Recruiting

Aurora, Colorado, United States, 80045-2517

Principal Investigator: Lentz Robert

United States, Texas

UT MD Anderson Cancer Center; Recruiting

Houston, Texas, United States, 77030

Principal Investigator: Meric-Bernstam Funda

Singapore

National University Hospital - Medical Oncology; Recruiting

Singapore, South West, Singapore, 119228

Principal Investigator: Yong Wei Peng

National Cancer Centre Singapore; Recruiting

Singapore, South West, Singapore, 168583

Principal Investigator: Ng Matthew

Sponsors and Collaborators

EDDC (Experimental Drug Development Centre), A*STAR Research Entities

Parexel

Investigators

• Study Director: Venkateshan Srirangam Prativadibhayankara, MD; EDDC (Experimental Drug Development Centre), A*STAR Research Entities

More Information

• Responsible Party: EDDC (Experimental Drug Development Centre), A*STAR Research Entities
• ClinicalTrials.gov Identifier: NCT05701527
• Other Study ID Numbers: EBC-129-01
• First Posted: January 27, 2023
• Last Update Posted: April 15, 2024
• Last Verified: April 2024

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by EDDC (Experimental Drug Development Centre), A*STAR Research Entities:

Advanced solid tumours; Antibody drug conjugates (ADCs); Recommended phase-2 dose (RP2D); Monomethyl auristatin E (MMAE); N-glycosylated CEACAM5/6

Additional relevant MeSH terms:

Neoplasms; Pembrolizumab; Antineoplastic Agents, Immunological; Antineoplastic Agents; Immune Checkpoint Inhibitors; Molecular Mechanisms of Pharmacological Action